Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bevacizumab

Bevacizumab ▴ Bevacizumab, a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor, inhibits tumor angiogenesis and delays disease progression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/bevacizumab-Tj3injnaYG
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403030-00005
Publisher site
See Article on Publisher Site

Abstract

▴ Bevacizumab, a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor, inhibits tumor angiogenesis and delays disease progression.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References